Acelyrin (SLRN) to Release Earnings on Monday

Acelyrin (NASDAQ:SLRN) will be issuing its quarterly earnings data after the market closes on Monday, May 13th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Acelyrin (NASDAQ:SLRN) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.25. On average, analysts expect Acelyrin to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Acelyrin Trading Up 2.4 %

SLRN opened at $4.35 on Monday. The stock has a market capitalization of $430.26 million and a P/E ratio of -0.41. The stock has a 50-day moving average price of $6.52 and a 200-day moving average price of $7.38. Acelyrin has a 12-month low of $4.14 and a 12-month high of $29.88.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on SLRN shares. HC Wainwright restated a “buy” rating and issued a $28.00 price objective on shares of Acelyrin in a report on Monday, April 1st. Wells Fargo & Company boosted their price target on shares of Acelyrin from $11.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 21st. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Acelyrin presently has an average rating of “Moderate Buy” and a consensus target price of $23.67.

Insider Buying and Selling at Acelyrin

In other Acelyrin news, CEO Shao-Lee Lin sold 15,701 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $7.60, for a total value of $119,327.60. Following the transaction, the chief executive officer now owns 1,587,335 shares in the company, valued at $12,063,746. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.